Compare Okta, Inc. (OKTA) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Pfizer Inc — how do they compare? Okta, Inc. trades at $222.3 (market cap $38.50B), while Pfizer Inc trades at $27.71 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.1× Okta, Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Pfizer Inc for 158 Days on average.
| OKTA | PFE | |
|---|---|---|
Market Cap | $38.50B | $158.56B |
Volume | 2,479,621 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $220.21 | $29.02 |
52-Week Low | $62.93 | $23.67 |
Typical Hold Time | 44 Days | 158 Days |
Enterprise Value | $36.25B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $218.00, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $2.61 billion in 2025 with a net income turnaround to $28 million. Recent earnings beats and positive analyst sentiment (73.58% buy ratings) highlight momentum, though high valuation ratios like a P/E of 131.33 pose concerns. Key developments include AI security initiatives unveiled at Oktane 2026, driving media attention.
Outlook: OKTA's focus on AI agent security and identity management positions it for growth in cybersecurity, but elevated valuations and insider selling require caution. Risks include competitive pressures and execution challenges. The consensus price target of $201.30 suggests modest downside, yet innovation catalysts offer long-term potential.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
